国药现代：李显林辞去公司副总裁等职务

Group 1 - The core point of the article is the resignation of Mr. Li Xianlin from his position as Vice President of China National Pharmaceutical Group Modern (国药现代) due to reaching retirement age, and he will not hold any positions in the company or its subsidiaries after his departure [2]. Group 2 - For the fiscal year 2024, the revenue composition of China National Pharmaceutical Group Modern is as follows: formulations account for 49.84%, intermediates and active pharmaceutical ingredients account for 47.53%, other businesses account for 2.44%, and health-related businesses account for 0.19% [2].